MAPT and Alzheimer disease: A successful example is Alzheimer’s disease (AD), where changes in CSF amyloid-β1–42 and phosphorylated tau isoforms reliably detect the underlying AD pathology even in the preclinical disease stages before the onset of overt clinical symptoms6.